Microparticles comprising GNRH made by PGSS

Patent metadata

Field	Value
Publication number	US-10441626-B2
Application number	US-201415027754-A
Country	US
Kind code	B2
Filing date	Oct 7, 2014
Priority date	Oct 8, 2013
Publication date	Oct 15, 2019
Grant date	Oct 15, 2019

Abstract

A pharmaceutical formulation comprising a solid matrix of one or more biodegradable polymers, the solid matrix including a pharmaceutically active substance or a pharmaceutically acceptable salt thereof distributed homogeneously or substantially homogeneously within the matrix; wherein the pharmaceutically active substance is, for example, a gonadotropin releasing hormone (GnRH), a GnRH agonist or a GnRH antagonist.

First claim

The invention claimed is:

1. A pharmaceutical formulation comprising a solid matrix of one or more biodegradable polymers and a pharmaceutically active substance or a pharmaceutically acceptable salt thereof,
wherein the active substance is distributed uniformly within the matrix on a micrometer scale and the active substance is chosen from gonadotropin releasing hormone (GnRH), a GnRH agonist, and a GnRH antagonist,
wherein the formulation is made by a process comprising the steps of:
(a) providing in a vessel the biodegradable polymer in solid form, the pharmaceutically active substance or salt thereof in solid form, and optionally an excipient;
(b) adding a solvent to the vessel which includes the polymer in solid form and the pharmaceutically active substance in solid form;
(c) adding a fluid which is capable of existing in a supercritical state to the vessel;
(d) increasing the temperature and pressure in the vessel to convert the fluid to the supercritical state, optionally mixing the polymer, pharmaceutically active substance, and excipient (if present) prior to, during, and/or after conversion of the fluid to the supercritical state;
(e) decreasing one or both of the temperature and pressure in the vessel to convert the fluid to a sub-critical state; and then increasing one or both of the temperature and pressure in the vessel to return the fluid to the supercritical state; and
(f) recovering the solid matrix.

2. The pharmaceutical formulation according to claim 1 , wherein the pharmaceutically active substance is degarelix.

3. The pharmaceutical formulation according to claim 2 , wherein the amount of degarelix in the pharmaceutical formulation is from 5% to 40% by weight of the solid matrix.

4. The pharmaceutical formulation according to claim 1 , further comprising one or more excipients.

5. The pharmaceutical formulation according to claim 4 , wherein the one or more excipient is distributed homogeneously or substantially homogeneously within the matrix.

6. The pharmaceutical formulation according to claim 4 , wherein the one or more excipient is chosen from a sugar, a sugar alcohol, an inorganic salt, and a synthetic polymer.

7. The pharmaceutical formulation according to claim 1 , wherein the biodegradable polymer is polyhydroxy acid (PHA).

8. The pharmaceutical formulation according to claim 7 , wherein the polyhydroxy acid (PHA) is chosen from poly(lactic acid) (PLA), poly(glycolic acid) (PGA), a copolymer of lactic and glycolic acid (PLGA), a copolymer of lactic and glycolic acid with poly(ethylene glycol), poly(e-caprolactone) (PCL), and poly(3-hydroxybutyrate) (PHB).

9. The pharmaceutical formulation according to claim 8 , wherein the biodegradable polymer is a copolymer of lactic and glycolic acid (PLGA).

10. The pharmaceutical formulation according to claim 9 , wherein the PLGA has a molar ratio of lactic acid:glycolic acid of from 90:10 to 10:90.

11. The pharmaceutical formulation according to claim 1 , wherein the inherent viscosity of the one or more biodegradable polymer is from about 0.1 to about 0.5 dL/g.

12. The pharmaceutical formulation according to claim 1 , wherein the solid matrix is in the form of microparticles.

13. The pharmaceutical formulation according to claim 12 , wherein the microparticles have mean particle size from about 25 to about 65 μm expressed as the volume mean diameter (VMD).

14. The pharmaceutical formulation according to claim 1 , wherein the formulation is in the form of a suspension.

15. The pharmaceutical formulation according to claim 14 , wherein the formulation further comprises a pharmaceutically acceptable carrier.

16. The pharmaceutical formulation according to claim 1 , wherein the formulation is in a form for intramuscular administration.

17. The pharmaceutical formulation according to claim 1 , wherein the fluid added in step (c) is carbon dioxide.

18. The pharmaceutical formulation according to claim 17 , wherein the solvent added in step (b) is an aprotic organic solvent.

19. The pharmaceutical formulation according to claim 18 , wherein the aprotic organic solvent is chosen from dimethyl sulfoxide (DMSO), acetone, and an alcohol.

20. The pharmaceutical formulation according to claim 19 , wherein the solid matrix is washed in water, a C 1 to C 8 alcohol, or a solution of a C 1 to C 8 alcohol in water.

21. A method of treating prostate cancer or benign prostate hyperplasia comprising:
administering to a patient in need thereof a pharmaceutical formulation comprising a solid matrix of one or more biodegradable polymers and a pharmaceutically active substance or a pharmaceutically acceptable salt thereof,
wherein the active substance is distributed uniformly within the matrix on a micrometer scale and the active substance is chosen from gonadotropin releasing hormone (GnRH), a GnRH agonist, and a GnRH antagonist
wherein the pharmaceutical formulation is made by a process comprising the steps of:
(a) providing in a vessel the biodegradable polymer in solid form, the degarelix or salt thereof in solid form, and optionally an excipient;
(b) adding a solvent to the vessel which includes the polymer in solid form and the degarelix in solid form;
(c) adding a fluid which is capable of existing in the supercritical state to the vessel;
(d) increasing the temperature and pressure in the vessel to convert the fluid to the supercritical state, optionally mixing the polymer, degarelix and excipient (if present) prior to, during, and/or after conversion of the fluid to the supercritical state;
(e) decreasing one or both of the temperature and pressure in the vessel to convert the fluid to a sub-critical state; and then increasing one or both of the temperature and pressure in the vessel to return the fluid to the supercritical state; and
(f) recovering the solid matrix.

22. The pharmaceutical formulation according to claim 1 , further comprising after step (e), repeating step (e) one or more times.

23. The pharmaceutical formulation according to claim 1 , further comprising after step (f), washing the solid matrix.

24. The pharmaceutical formulation according to claim 1 , wherein the pharmaceutically active substance is triptorelin.

25. The pharmaceutical formulation according to claim 21 , further comprising after step (e), repeating step (e) one or more times.

26. The pharmaceutical formulation according to claim 21 , further comprising after step (f), washing the solid matrix.

27. A method of making a pharmaceutical formulation comprising an active substance or pharmaceutically acceptable salt thereof is distributed uniformly within a matrix on a micrometer scale, the method comprising:
(a) providing in a vessel a biodegradable polymer in solid form, the active substance or salt thereof in solid form, and optionally an excipient;
(b) adding a solvent to the vessel which includes the polymer in solid form and the active substance or salt thereof in solid form;
(c) adding a fluid which is capable of existing in the supercritical state to the vessel;
(d) increasing the temperature and pressure in the vessel to convert the fluid to the supercritical state, optionally mixing the polymer, the active substance or salt thereof and excipient (if present) prior to, during, and/or after conversion of the fluid to the supercritical state;
(e) decreasing one or both of the temperature and pressure in the vessel

Assignees

• Ferring Bv

Inventors

• Schwach Gregoire Charles Joseph
• Schiefelbein Lars
• Naylor Andrew
• Whitaker Mark Andrew
• Arrowsmith Nicholas John

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P13/08

  of the prostate · CPC title

• A61K38/22

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title

• A61K9/1647 Primary

  Polyesters, e.g. poly(lactide-co-glycolide) · CPC title